ABVC BioPharma Secures Japanese Patent for Innovative Depression Treatment
ABVC BioPharma has obtained a Japanese patent for its botanical-based Major Depressive Disorder treatment ABV-1504, expanding its global intellectual property portfolio and positioning the company for potential market entry in Japan's robust pharmaceutical landscape.
Biopharmaceutical company ABVC BioPharma has secured a patent in Japan for its Major Depressive Disorder (MDD) treatment candidate ABV-1504, strengthening its global intellectual property strategy. The patent, valid through 2040, provides protection for PDC-1421, the active botanical ingredient derived from Polygala tenuifolia.
The development is significant in the context of a global mental health market where MDD affects over 280 million people worldwide, with the antidepressant market projected to reach $20 billion by 2030. ABV-1504 offers a differentiated approach as a botanical-based alternative to traditional selective serotonin reuptake inhibitors (SSRIs), positioning itself as a potentially safer, non-addictive treatment option.
Japan represents a strategic market for the company, with its mature pharmaceutical sector and a receptive healthcare system that integrates botanical medicines. The country's antidepressant market is expected to reach $1.25 billion by 2025, and more than 5 million individuals are affected by depression.
The patent is part of a broader intellectual property portfolio that now includes protection in the United States, Australia, Taiwan, and Japan. This comprehensive coverage follows a significant $667 million global licensing agreement with AiBtl BioPharma, which positions ABVC to potentially unlock substantial value in the CNS therapeutics market.
Through its joint venture BioLite Japan K.K., ABVC is actively engaging in local market expansion, leveraging relationships with regulatory bodies, academic institutions, and industry partners to introduce its innovative botanical-based treatment.